EUCTR2004-005210-37-DE进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Able and willing to give written informed consent and comply with the requirements of the study protocol.
- •2.Patients with rheumatoid arthritis of ³ 6 months duration diagnosed according to the revised 1987 American College of Rheumatology (ACR; formerly American Rheumatism Association) criteria (Appendix 2).
- •3.Receiving treatment on an outpatient basis.
- •4.Prior to randomization, will have discontinued etanercept for ³ 2 weeks, infliximab or adalimumab for ³ 8 weeks (see exclusion # 5), anakinra for ³ 1 week.
- •5.Have received permitted DMARDs, each at a stable dose, for at least 8 weeks prior to baseline.
- •6.Swollen joint count (SJC) ³ 6 (66 joint count) and tender joint count (TJC) ³ 8 (68 joint count) at screening and baseline.
- •7.At screening either CRP ³ 1 mg/dL (10 mg/L) or ESR ³ 28 mm/hr
- •8.Age ³ 18 years
- •9.Oral corticosteroids (£ 10 mg/day prednisone or equivalent) and NSAIDs (up to the maximum recommended dose) are permitted if the dose has been stable for at least 6 weeks prior to baseline.
- •10.Females of child-bearing potential and males with female partners of child-bearing potential may participate in this trial only if using a reliable means of contraception (e.g. physical barrier (patient and partner), contraceptive pill or patch, spermicide and barrier, or IUD).
- •11.If female and of childbearing potential, the patient must have a negative urine pregnancy test within three weeks prior to baseline.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Major surgery (including joint surgery) within eight weeks prior to screening or planned surgery within six months following randomization.
- •2.Rheumatic autoimmune disease other than RA, including SLE, MCTD, scleroderma, polymyositis, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty’s syndrome). Sjögren’s Syndrome with RA is allowable.
- •3.Functional class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis.
- •4.Prior history of or current inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease).
- •Excluded Previous or Concomitant Therapy:
- •5.Unsuccessful treatment with an anti-TNF agent (i.e. significant safety issues or lack of efficacy; Patients who terminated previous anti-TNF treatment due to cost or discomfort with the subcutaneous injections, may participate in this study.) (See Inclusion #4 for anti-TNF agent washouts.)
- •6.Treatment with any investigational agent within four weeks (or five half-lives, whichever is longer) of screening.
- •7.Previous treatment with any cell depleting therapies, including investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19 and anti-CD20).
- •8.Treatment with intravenous gamma globulin, plasmapheresis or Prosorba ä column within six months of baseline.
- •9.Intra-articular or parenteral corticosteroids within six weeks prior to baseline.
- •10.Immunization with a live/attenuated vaccine within four weeks prior to baseline.
- •11.Previous treatment with MRA (an exception to this criterion may be granted for single dose exposure upon application to the sponsor on a case by case basis).
- •12.Any previous treatment with alkylating agents such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation.
- •Exclusions for General Safety
- •13.History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies.
- •14.Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (incl. obstructive pulmonary disease), renal, hepatic, endocrine (incl. uncontrolled diabetes mellitus) or gastrointestinal disease.
- •15.Uncontrolled disease states, such as asthma, psoriasis or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids.
- •16.Current liver disease as determined by principal investigator. (Patients with prior history of ALT elevation will not be excluded.)
- •17.Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, granulomatous disease on chest X-ray, Hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with IV antibiotics within four weeks of screening or oral antibiotics within two weeks prior to screening.
- •18.Primary or secondary immunodeficiency (history of or currently active).
- •19.History of malignancy, including solid tumors and hematologic malignancies (except basal cell carcinoma of the skin that has been excised and cured).
- •20.Pregnant women or nursing (breast feeding) mothers.
- •21.History of alcohol, drug or chemical abuse within the six months prior to screening.
- •22.Neuropathies or other painful conditions that might in
研究者
相似试验
进行中（未招募）
Unknown
actoSpore® as an adjuvant in the treatment of Bacterial VaginosisCTRI/2023/05/052560Sami Sabinsa Group Limited
进行中（未招募）
1 期
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859EUCTR2019-003656-37-HRMenarini International Operations Luxembourg SA510
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability of 14-days treatment with an inhaled dose of QMF149 (500/800) in mild to moderate asthmatic patients.asthmaEUCTR2007-004608-11-FRovartis Pharma Services AG28
已完成
不适用
Boswellia serrata extract 200 mg capsules in subject with Irritable Bowel Syndrome.CTRI/2019/11/022190Inventia Healthcare Limited50
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of a 4-week treatment of 30 mg b.i.d BIBW 2948 BS (inhalation powder, hard capsule for HandiHaler®) on epithelial mucin stores and the safety and efficacy in COPD patients with symptoms associated with chronic bronchitis - Effects of BIBW 2948 on epithelial muciEUCTR2006-001975-40-IEBoehringer Ingelheim Limited60